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Abstract:
Background:
The optimal antiplatelet therapy (APT) treatment strategy after Coronary Artery Stenting (CAS) in non-cardiac surgery, such as total
knee arthroplasty (TKA) or urgent TKA-related surgery remains unknown.
Methods:
We built  a  decision  tree  model  to  examine  the  mortality  outcomes  of  two  alternative  strategies  for  APT  after  CAS  use  in  the
perioperative period namely, continuous use and discontinuation.
Results:
If surgery was performed in the first month after CAS placement, discontinuing APT led to an estimated 30-day post TKA mortality
of 10.5%, compared to 1.0% in a strategy with continuous APT use. Mortality with both strategies decreased with longer intervals.
Conclusion:
Our model demonstrated that APT discontinuation in patients undergoing TKA or urgent TKA related surgery after CAS placement
might lead to greater 30-day mortality up to one year.
Keywords: Clopidogrel, Coronary stenting, Mortality, Plavix, Revision total knee arthroplasty, Total knee arthroplasty.
INTRODUCTION
In  1990,  bare-metal  coronary  artery  stent  (CAS)  implantation  was  introduced  and  revolutionized  percutaneous
coronary intervention. It significantly reduced abrupt vessel closure and restenosis after balloon angioplasty [1]. Drug-
eluting stents were developed to address the neointimal hyperplasia at the site of bare-metal stent implantation that often
caused restenosis [2]. The endothelial trauma caused by the implantation of a stent makes anticoagulation therapy with
antiplatelet  medication  necessary  to  prevent  intraluminal  thrombosis.  Over  1,000,000  coronary  interventions  are
performed annually in the United States [3]. Non-cardiac surgery has been documented to occur in at least 5% of stent
recipients within the first year after CAS placement [4, 5]. It has been reported that of the patients undergoing CAS
placement, orthopaedic procedures account for approximately 20-33% of all subsequent non-cardiac surgeries [5, 6].
Among  all  orthopaedic  procedures, total  knee  arthroplasty  (TKA)  remains one of  the  most  commonly  performed
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surgeries and its utilization is increasing [7].
Dual  antiplatelet  therapy,  typically  consisting  of  either  thienopyridines  (clopidogrel  [Plavix,  Sanofi-Aventis,
Bridgewater, NJ] or ticlopidine [Ticlid, Hoffmann-LA Roche Inc, Nutley, NJ]) in combination with aspirin therapy, has
been recommended in the prevention of early artery stent thrombosis. It is, however, often a concern to the orthopaedic
surgeon performing a procedure due to the increased bleeding risk [8].
The management of anticoagulation among recipients of CAS who undergo non-cardiac procedures, such as TKA,
has not been standardized and remains controversial. The American College of Cardiology/American Heart Association
practice guidelines recommend continuing thienopyridine therapy plus aspirin for up to a year, depending on the type of
the stent, to avoid stent thrombosis and restenosis [9, 10]. However, patients who experience significant quality of life
reduction  due  to  symptomatic  knee  osteoarthritis  or  in  the  setting  of  an  urgent  TKA related  complication  such  as
periprosthetic  fracture  may  not  able  to  wait  until  the  one-year  time  interval  has  elapsed.  Due  to  the  known  high
morbidity  of  hematoma  formation  and  the  possibility  of  infection  after  TKA or  TKA related  surgery,  orthopaedic
surgeons may opt for cessation of oral antiplatelet therapy (APT) therapy. To our knowledge, there are no treatment
guidelines that aid in the decision making of perioperative APT management in the setting of TKA or TKA related
procedures.
We therefore undertook a model-based evaluation of 30-day mortality post TKA or urgent TKA related surgery
using  the  available  published  literature  parameters  to  quantify  the  trade-offs  between  a  potential  postoperative
hematoma and subsequent infection and mortality risk due to stent thrombosis that is closely associated with premature
cessation of antiplatelet agents.
We  used  a  decision  analysis  model  that  is  a  useful  tool  in  assisting  physicians  to  determine  the  best  clinical
management option in uncertain areas.  It  is  useful  since it  provides a more structured approach to evidence- based
decisions [11].
METHODS
Analytic Overview
We constructed a decision tree to discern the 30- day mortality in patients undergoing either primary TKA surgery
or  urgent  TKA  related  surgery  for  complications  such  as  periprosthetic  infection  or  periprosthetic  fracture.  Since
mortality decreases drastically with a longer duration between CAS placement and TKA, we conducted three stratified
analyses according to the time interval between CAS placement and TKA or TKA related surgery: 0-30 days, 1 month-
6 months and 6 months- 1 year (Fig. 1). We considered two alternative treatment strategies for APT: 1) leaving patients
on APT (continuous APT), or 2) taking patients off APT in the perioperative period of TKA or TKA-related surgery
(discontinued APT).  The APT regimen consisted of  aspirin in  combination with either  thienopyridine (Clopidogrel
[Plavix, sanofi-aventis, Bridgewater, NJ] or ticlopidine [Ticlid, Hoffmann-LA Roche Inc, Nutley, NJ]). Patients in the
first treatment group received both Plavix and Aspirin perioperatively without discontinuation. The second treatment
group discontinued aspirin and Plavix pre-operatively, at least three days prior to the operative intervention and was
restarted most commonly on the first postoperative day. All transition probabilities were derived from the published
literature  or  estimated  using  expert  opinion  when  data  were  not  available.  The  analysis  was  conducted  using  a
commercially available decision analysis software package (TreeAge Pro 11, TreeAge software, Williamstown, MA).
Model Structure
Our decision tree is depicted in Fig. (2). The principal decision consisted of either discontinuation or continuation of
the APT prior to TKA or TKA-related surgery in a patient who underwent prior CAS placement. The analysis was
conducted separately for each of the three different time intervals between CAS placement and TKA. In the model, after
the prosthesis implantation, patients either had a successful postoperative course without any complications or suffered
from hematoma formation or cardiac complications. Hematoma formation after a TKA does not only cause pain and
possible stiffness but is a major source for infection [12, 13]. Cardiac complications, such as stent thrombosis that lead
to myocardial infarction, carry a well-recognized high mortality rate. It was assumed that the chance of infection after
hematoma formation in the knee would be the same for both treatment strategies.
Decision analysis is an analytic approach that quantifies the benefits and adverse events of alternative treatment
strategies in a probabilistic manner using published data as input parameters. Impact of uncertainty in input parameters
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on outcomes is evaluated in sensitivity analysis [14].
Fig. (1). Timeline of Coronary stent (CAS) placement and Total knee arthroplasty or related surgery. 30-day mortality was calculated
for each time interval between CAS placement and TKA or related surgery. The first time interval from CAS and TKA was within
the 30 days, the second from 1 month to 6 months, and the third from 6 months to 1year.
Fig. (2). Decision tree model of the two Treatment Strategies following coronary stent placement and subsequent TKA. It was used
separately for the three different time intervals.
Model Parameters
Population
We considered a hypothetical cohort of individuals with advanced osteoarthritis requiring a primary TKA or surgery
to address complication of TKA such as periprosthetic infection or periprosthetic fracture.
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Base Case
Transition probabilities used in the model are shown in Table 1. Bleeding after TKA was defined as hematoma that
required  surgical  evacuation  or  as  moderate  postoperative  bleeding  using  the  American  College  of  Cardiology/
American Heart Association guidelines [15]. Rates of deep infection after hematoma (11.9%) were derived from Galat
et al. [12] The mortality associated with periprosthetic infection was derived from Cierny et al. [16]
Table 1. Input parameters for model-based evaluation of Continuation and Discontinuation of antiplatelet medication in
TKA patients with history of CAS surgery (in %).
Strategy Time interval between CAS and TKA
0-30 d 1- 6 mo 6 mo- 1 yr Range (%) Reference:
Discontinue APT Hematoma/
bleeding
31.0 9.3 2.4 0.2- 31.0 [17-19, 41]
Cardiac Event 23.2 9.5 7.0 6.0-37.5 [17, 20, 27-29, 42]
Death related to Cardiac Event 44.9 24.9 19.8 0.2-85.7 [6, 17, 22, 28, 34, 35, 42-44]
Continue of APT Hematoma/ bleeding 26.1 21.0 9.5 9.5- 43.8 [20-25]
Cardiac Event 7.4 3.2 3.0 0.6- 25.2 [5, 6, 21, 23, 25, 26]
Death related to Cardiac Event 12.3 8.3 3.2 0.2- 27.0 [4-6, 18, 22, 28, 35]
Common Variables
Infection after hematoma 11.9 11.9 [12, 13]
Death related to Infection 4.7 N/A [16]
Death unrelated to Infection and Cardiac
Complications
0.2 N/A [45]
Hematoma Risk
There is paucity of clinical data on hematoma risk in patients who undergo TKA or TKA related surgery in the first
30  days  after  CAS.  One  study  suggested  [17]  significant  major  bleeding  occurred  in  up  to  31.0% of  patients  who
underwent non-cardiac procedures (such as TKA) in the first 30 days after CAS while having discontinued their APT
medication. The averaged published risk of hematoma formation was found to be at 9.3% between 1 and 6 months [17,
18] and in 2.4% between 6 months and 1 year [19] in all other groups that discontinued APT.
Continuation of APT  resulted in a probability of moderate to severe bleeding in up to 43.8% but at averaged at
26.1% in the first 30 days [20 - 23] after CAS, 21.0% in the time lag of 1- 6 months [24] and 6.0% of between 6 months
and a year [25].
Risk of Cardiac Complications
Patients that discontinued APT prior to TKA or TKA-related surgery the risk of cardiac complications was 23.2% in
the first 30 days post CAS placement [17, 20, 21, 26, 27], 9.5% if TKA was done between 1 and 6 months post CAS
placement [17, 28], and 7.0% if TKA was performed between 6 months and 1 year post CAS placement [28, 29].
The risk of a patient with a history of a CAS suffering a cardiac complications in the postoperative period of a TKA
while  being on APT  was  7.4% during the  first  30 days  after  CAS placement  [5,  6,  23,  30],  3.2% between 1  and 6
months [5, 21, 30] and 3.0% between 6 months and 1 year [5, 6, 30].
Sensitivity Analysis
Some of the published data used for the computed model may not correspond to clinical experience. Therefore, to
determine the rates of complications and account for the variations in the treatment strategies that would influence the
decision to continue or to discontinue APT in those patients that undergo TKA or TKA related surgery, we conducted a
threshold analysis [31]. The threshold is defined as the lowest probability at which the decision in favor of terminating
antiplatelet regimen yields a lower expected mortality rate than the decision against. A low threshold implies a strong
indication for a particular therapy.
We conducted sensitivity analysis to evaluate the effect of each variable on the outcome of the model. If a change of
one  variable  alters  the  treatment  strategy,  the  model  is  considered  “sensitive”  to  that  variable;  if  not,  the  model  is
deemed “robust”.
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RESULTS
Mortality
The 30- day mortality after TKA or urgent TKA related surgery in patients with a history of recent (0-30 days) CAS
placement and who discontinued APT prior to TKA, was calculated at 10.7% compared to an estimated 1.2% when
APT was continued perioperatively. In patients that had a history of CAS between 1 month and 6 months prior to TKA,
the 30- day mortality dropped to 2.6% in the group that discontinued APT versus 0.5% in those that continued APT.
The 30- day mortality risk further dropped for patients undergoing TKA who had CAS between 6 months to 1 year
prior to TKA to 1.6% (discontinued APT) and 0.3% among those who continued APT. (Fig. 3).
Fig. (3). Estimated 30-day mortality risk after bleeding/ cardiac complications/ hematoma formation when antiplatelet therapy was
dis/continued during TKA, APT= Antiplatelet Therapy.
Sensitivity Analyses
30-Day Mortality Risk Related to Cardiac Complication
In order to achieve an equal 30- day mortality risk in both treatment strategies (continuation and discontinuation of
APT) for patients who had CAS placement 0- 30 days prior to TKA, cardiac complications needed to drop from an
average reported risk of 23.2% in the group who discontinued APT to 2.2% -- an approximate ten-fold decrease.
For those with a history of CAS placement between 1 month and 6 months from TKA, the necessary threshold was
calculated  to  be  at  1.4%,  a  seven-fold  drop  from  the  original  9.5%  risk  of  cardiac  complications  in  those  with
discontinued APT.
The necessary threshold for  cardiac complications in those patients,  who underwent  CAS placement  between 6
months and 1 year from TKA, was 0.7% from an initial 7.0%.
30-Day Mortality Risk Related to Death from Cardiac Complications
Further  threshold  analysis  demonstrated  that  if  the  risk  of  death  related  to  cardiac  complications  with  APT
discontinuation decreased below 4.3%, 3.7% and 9.5% from the initial published risks of 44.9%, 24.9% and 19.8% for
the three time intervals between CAS and TKA or TKA related surgery,  discontinuation would lead to lower post-
operative mortality compared to the continuation of APT (Table 2).
Beyond 1 year, there was a minimal difference in the 30-day mortality risk (not shown) between both treatment
strategies and small variations in the different variables could favor either regimen.
 
0.0%
2.0%
4.0%
6.0%
8.0%
10.0%
12.0%
0-30 d 1- 6 mo 6 mo- 1 yr
30-Day Mortality risk of the first three time 
intervals
Discontinue APT
Continue APT
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Table  2.  Threshold  analysis  for  cardiac  complications  to  favor  discontinuation  of  Antiplatelet  Therapy  and  original
probabilities  of  cardiac  complications  when  antiplatelet  therapy  was  discontinued.  APT=  Antiplatelet  Therapy.
Variables 0-30 days 1-6 mo 6mo- 1 yr
Reduction necessary to reach threshold to favor Discontinuation of APT 40.6% 21.2% 10.3%
Threshold to favor Discontinuation of APT 4.3% 3.7% 9.5%
30-Day Mortality Risk Related to Hematoma Formation
Patients who continued APT were reported to have a bleeding risk ranging from 9.5% to 43.8% in the three different
time intervals after CAS. Although this is a wide range and a very high percentage rate, it did not substantially affect the
30-day mortality in any of the time intervals as the risk of cardiac complications had a stronger affect on mortality.
DISCUSSION
We  reported  on  the  30-day  mortality  risk  of  two  different  treatment  strategies  involving  the  perioperative
discontinuation or  continuation of  APT in patients  with a  history of  a  CAS placement  before TKA or  urgent  TKA
related surgery such as infection or periprosthetic fracture. We used published data for the computed model and applied
a wide sensitivity analysis to account for variations.
We found that the 30-day mortality risk in patients with a history of CAS placement who discontinued APT prior to
TKA or urgent TKA related surgery was higher compared to those patients who continued with APT for up to a year. In
the  first  time  interval  of  0-30  days  post  CS  placement,  the  30-day  mortality  of  TKA or  TKA related  surgery  was
calculated to be at 10.7% when APT was discontinued which was driven by the death related to cardiac complications
and dropped to 2.6% and 1.6% in subsequent two time intervals (1- 6months and 6 months- 1 year). This is in contrast
to 1.2%, 0.5% and 0.3% 30- day mortality risk in patients that continued APT, respectively.
There is a lack of consensus on the “safe” timing of orthopedic surgery after CAS, on the decision of continuation or
discontinuation  of  APT  prior  to  the  procedure  and  if  APT  is  stopped,  the  number  of  days  that  APT  should  be
discontinued  [32].  With  an  aging  population  and  associated  obesity  and  diabetes,  which  are  main  risk  factors  for
cardiovascular  disease  the  number  of  percutaneous  interventions  are  likely  to  increase.  In  fact,  the  number  of
percutaneous interventions tripled over the period between 1988 to 2001 from 80.3 per 100,000 [95%CI: 71.9-88.9] in
1988  to  244  per  100,000  [95%CI:  221.3-266.4,  p<0.01]  in  2001  in  the  United  States  [33].  Delaying  orthopedic
procedures for osteoarthritic conditions such as a TKA or urgent TKA related procedures due to the presumed increased
risk  from cardiac  complications  that  may  ensue  from recent  CAS could  lead  to  worsening  impact  on  the  patient’s
quality of life [33]. Therefore, it is often left to the orthopaedic surgeon and the patient’s PCP and/or cardiologist to
balance risk and benefits of the two main treatment strategies of APT when surgery is necessary.
Previous studies reported variable outcomes, including complications, such as cardiac events that may lead to death
of non-cardiac surgery after drug-eluting stents or bare metal stents [5, 6, 18, 20, 22 - 24, 27 - 29, 34 - 36]. Drug-eluting
stents have been reported to be associated with a higher rate of early restenosis and it has therefore been suggested to
have those patients complete a full year of APT. It has been recommended to delay elective non-cardiac surgery >14
days for balloon angioplasty, >30-45 days for bare metal stents and >365 for drug eluting stents [37].
Small-scale studies have underscored the importance of completing a full course of one year of APT in the setting of
necessary non-cardiac surgery [6]; however these findings are yet to be confirmed by larger and preferably randomized
series. Kaluza and colleagues [20] were among the first to report on adverse events after CAS placement in patients
who subsequently underwent non-cardiac surgery. In their study, the authors retrospectively assessed 40 patients who
underwent non-cardiac surgery after recent CAS and reported on seven myocardial infarctions, 11 severe bleeds and
eight deaths. In contrast to our study, they were not able to control for continuation or discontinuation of APT.
We used the available data from the literature and created two distinct treatment arms that allowed us to identify the
strategy that was associated with a lower mortality rate followed by a sensitivity analysis to account for the variations of
the  treatment  strategies.  Vicenzi  et  al.  [4]  prospectively  analyzed  103  patients  that  underwent  non-cardiac  surgery
within  the  first  year  of  CAS  placement.  APT  was  either  withdrawn  3  days  prior  to  the  surgery  or  was  continued
throughout  the  perioperative  period.  In  almost  half  of  the  patients  (n=46),  complications  occurred  postoperatively,
consisting of 42 who had a cardiac event and two who had bleeding. They found an increased risk of adverse events in
the immediate period after CAS placement (<35 days) compared to CAS placement more than 90 days prior to non-
cardiac surgery. Their results are comparable to our findings. Cardiac complications appear to be the main risk in the
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perioperative period following non- cardiac surgery in the patient with recent CAS.
Maintaining non-cardiac surgery patients on APT increases the risk of bleeding as shown by Wilson et al. [23] who
documented the need for blood transfusions in 33% of patients who underwent non-cardiac surgery including vascular,
orthopaedic, genitourinary and gastrointestinal procedures while on APT. However, no studies have found a significant
impact on overall mortality.
Using data from multiple data sources, our analysis was able to confirm this finding. In the current study, bleeding
risk  in  patients  who  were  kept  on  APT  ranged  from  9.5%  to  43.8%,  which  did  not  influence  the  overall  30-  day
mortality for up to a year. A study reported [17] that patients who discontinued APT preoperatively for up to 7 days
demonstrated an initial high bleeding risk (31.0%) in the first two weeks, which may reflect that patients may be at
higher risk of bleeding in the first 30 days regardless of continuing or discontinuing APT. This may not reflect clinical
expertise but this finding did not offset our sensitivity analysis. The mortality risk related to infection after hematoma
formation or moderate to severe bleeding is low and therefore had little impact on the 30-day mortality compared to the
30-day mortality caused by cardiac complications. However, we were unable to measure morbidity related to hematoma
formation with a potential of infection after TKA surgery.
It is noteworthy that there are several definitions of hematoma formation. While some define hematoma formation
as the need for re-operation for bleeding [38] others such as the American College for Cardiology and American Heart
Association elect to use the term “moderate hematoma” as a surrogate for hematoma formation [39]. We elected to use
the later to potentially overestimate the amount of hematoma formation on purpose. Hematoma formation in essentially
all patients with a 50% infection risk would favor the perioperative discontinuation of Plavix at any given time interval.
Jacob et al. [40] performed a retrospective analysis on 142 patients undergoing arthroplasty while being either off or
on Plavix perioperatively and determined 30- day readmission, reoperation, hematoma formation. 3 patients developed
bleeding and one infectious complication in the group that discontinued Plavix. They were unable to state the diagnosis
for which Plavix was prescribed nor was there sufficient data on when a coronary stent was placed and the time lag
between  the  coronary  stent  and  the  arthroplasty.  We  used  their  data  on  hematoma  formation  and  transfusion
requirement for our sensitivity analysis and our results were not impacted by their findings. Nandi et al. [38] performed
a retrospective study assessing the effect of Plavix in the perioperative setting. They included patients being on Plavix
for a prior stroke and peripheral vascular disease as well as a prior coronary stent. The data presented did not disclose
the  time  between  stenting  and  arthroplasty.  Interestingly,  there  was  no  statistical  difference  between  hematoma
formation in either group of patient’s undergoing arthroplasty, however they noted a higher incidence of reoperation for
hematoma formation  in  revision  arthroplasty  while  being  on  Plavix.  Similarly,  using  their  data  did  not  impact  our
conclusions since the risk of hematoma formation has little impact on mortality.
While in clinical practice surgeons may consider other strategies related to discontinuation of Plavix or aspirin or
both,  currently  there  is  no  published  literature  reporting  differential  hematoma  formation  rates  among  alternative
clinical strategies beyond those described in our analysis. Further, results of our extensive sensitivity analyses suggested
that variability in rates of hematoma had no effect on ranking of the strategies.
The important finding of this study is that the risk of hematoma formation that may be due to continuation of Plavix
in the first year after coronary stenting has a minimal effect on the mortality since discontinuing Plavix increases the
risk of cardiac complications, which is associated with a high mortality rate. For example, when TKA is performed
between 1 month and 6 months after coronary stenting, the hematoma formation would have to virtually affect every
patient (99%) with a risk of hematoma formation of 50% to offset the discontinuation of Plavix and cause a higher
mortality.
Due to the heterogeneity of the available literature, limitations included the inability to differentiate between the
type, number, length and diameter of the stent. This is a potential bias as it has been shown, that longer, drug-eluting
stents may result in earlier occlusion. Further, it is known that CAS after acute coronary syndrome are associated with a
higher incident of adverse events [6].
Other limitations consisted of the fact that we could neither differentiate between types of non-cardiac surgery, nor
the overall health status of the assumed cohort that might have influenced the model. It is likely that TKA has a lower
complication rate than, for example, elective vascular surgery. Similarly, a lower NYHA status could influence the
outcome of cardiac complications. We therefore conducted a wide set of sensitivity analysis to evaluate the robustness
of the model. In all simulated cases, cardiac complications were required to fall significantly up to eight fold to achieve
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a lower 30-day mortality risk than in the group that continued APT for up to year. The published data were too sparse
and heterogeneous to permit stratification by diabetes, renal failure, different location of coronary artery stenosis and
stent types, low ejection fraction and prior surgeries that could potentially skew the results, except for stenosis of the
coronary vessels requiring intervention. We do not have external data against which we can validate the performance of
the model. In these circumstances, sensitivity analyses are valuable tools for investigating the range of outcomes that
might be expected from plausible swings in key input parameters. These analyses are particularly useful in models such
as ours in which most input parameters were derived from observational and retrospective studies in the absence of
randomized controlled trials.
This is the first study to our knowledge that elucidates the 30- day mortality risk of three different time intervals in
patients  who  underwent  CAS  placement  and  subsequent  TKA or  urgent  TKA related  surgery  such  as  infection  or
periprosthetic fracture. Although there are several limitations to this study, sensitivity analysis revealed the robustness
of the decision model.
CONCLUSION
In conclusion, our data suggest that delaying TKA for at least 1 year after percutaneous CAS placement leads to
substantial reduction in 30-day post-TKA mortality. In almost all scenarios, terminating APT prior to TKA or urgent
TKA  related  surgery  in  the  first  year  after  percutaneous  CAS  placement  carries  a  higher  30-day  mortality  than
continuing APT perioperatively. We were, however unable to determine morbidity. The continuation of perioperative
APT did not appear to have an influential effect on the rate of increased hematoma formation and subsequent infection
rate. Therefore, postponing an elective TKA may lead to a substantial reduction in post- TKA mortality. Whenever
urgent TKA related surgery is required, the orthopaedic surgeon should weigh risks and benefits of death, major cardiac
issues and the deleterious effects of hematoma with each other. The complexity of this decision for every patient should
prompt close consultation with the primary care physician, cardiologist and/or cardiologic interventional physician to
provide the best possible outcome for the patient.
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